The cell surface sialyl Lewis a (sLe a ) and sialyl Lewis x (sLe x ) antigens, which are built on the terminals of glyco-structures called poly-N-acetyllactosamine (LacNAc) chains, have been shown to play a critical role in the metastasis of colon cancer. In the present investigation, expression of the B3GNT7 gene, which encodes a β-1,3-N-acetylglucosaminyltransferase that mainly acts on and extends sulfated poly-LacNAc chains, was found to be markedly suppressed during the oncogenetic processes associated with colon cancer. DNA methylation in the promoter region of the B3GNT7 gene was found to play a significant role in the suppression of the B3GNT7 gene in colon cancer cells. The results obtained from Transwell experiments and the nude mice xenograft model demonstrated that ectopic expression of the B3GNT7 gene in colon cancer cells diminished the migration capability and the liver-metastasis potential, respectively, of colon cancer cells. Flow cytometric analysis showed that expression of cell surface sLe a and sLe x antigens was decreased in colon cancer cells when the B3GNT7 gene was ectopically expressed. Taken together, the results of the present investigation suggest a link between suppression of B3GNT7 gene expression and elevation of sLe a / sLe x antigen expressions on the surface of cells and that this consequently promotes the metastasis potential of cancer cells as part of the colon cancer oncogenetic process.
The cell surface sialyl Lewis a (sLe a ) and sialyl Lewis x (sLe x ) antigens, which are built on the terminals of glyco-structures called poly-N-acetyllactosamine (LacNAc) chains, have been shown to play a critical role in the metastasis of colon cancer. In the present investigation, expression of the B3GNT7 gene, which encodes a β-1,3-N-acetylglucosaminyltransferase that mainly acts on and extends sulfated poly-LacNAc chains, was found to be markedly suppressed during the oncogenetic processes associated with colon cancer. DNA methylation in the promoter region of the B3GNT7 gene was found to play a significant role in the suppression of the B3GNT7 gene in colon cancer cells. The results obtained from Transwell experiments and the nude mice xenograft model demonstrated that ectopic expression of the B3GNT7 gene in colon cancer cells diminished the migration capability and the liver-metastasis potential, respectively, of colon cancer cells. Flow cytometric analysis showed that expression of cell surface sLe a and sLe x antigens was decreased in colon cancer cells when the B3GNT7 gene was ectopically expressed. Taken together, the results of the present investigation suggest a link between suppression of B3GNT7 gene expression and elevation of sLe a
Introduction
Aberrant glycosylation has been found to occur in various cancers (Hakomori 1989 (Hakomori , 1996 (Hakomori , 2002 and specific glyco-epitopes have been identified as playing critical roles in the oncogenesis of several types of cancers (Fukuda 1996; Kannagi 1997; Hakomori 2002; Ono and Hakomori 2004) . In colon cancers, it has been demonstrated that the cell surface antigens sialyl Lewis a (sLe a ) and sialyl Lewis x (sLe x ), characterized as NeuAcα2-3Galβ1-3 (Fucα1-4)GlcNAcβ1-and NeuAcα2-3Galβ1-4(Fucα1-3) GlcNAcβ1-, respectively, are functionally significant during cancer cell metastasis. Elevated expression of sLe a and sLe x antigens occurs frequently in colon cancer cells (Nakagoe et al. 1993; Nakamori et al. 1993; Shimono et al. 1994; Nakayama et al. 1995) ; these glyco-epitopes bind with E-selectin, which is expressed on the endothelial cells of blood vessels, and this facilitates metastasis (Kannagi 1997) . Thus, it has been widely recognized that sLe a /sLe x cell surface antigens act as signals for the hematogenous metastasis of colon cancer cells. In this context, attempts to elucidate the molecular mechanisms leading to elevated expression of the sLe a /sLe x antigens during the oncogenetic processes of colon cancer and, further, to develop specific measures to inhibit their formation or to block the recognition between these epitopes and E-selectin on endothelial cells have attracted considerable attention. sLe a /sLe x antigenic epitope formation involves α-2,3-sialyltransferase and α-1,4-fucosyltransferase/α-1,3-fucosyltransferase. The antigens are constructed at the terminals of the glyco-chains, which consist of N-acetyllactosamine (LacNAc) unit repeats, called poly-LacNAc chains; these are synthesized by the sequential action of β-1,3-N-acetylglucosaminyltransferase (β3GlcNAcT or β3GnT) and β-1,4-galactosyltransferase (β4GalT) (Fukuda 2001; Stanley, et al. 2009 ). Most of the glycosyltransferases responsible for the synthesis of sLe a /sLe x and the poly-LacNAc backbones are members of a family of homologous enzymes. This situation complicates the studies of the formation and expression of sLe a /sLe x at molecular level. In addition, structural alterations and modifications to the poly-LacNAc chains are known to markedly affect the synthesis and expression of the sLe a /sLe x antigens on the poly-LacNAc terminals. These may include sulfation (Izawa et al. 2000) , α-2,6-sialylation ) and the Sd a glyco-epitope formation (Kawamura et al. 2005 ) and others. Furthermore, it has been suggested that the functionality of the membrane transporters responsible for transporting monosaccharides into cells and the enzymes responsible for the biosynthesis of the donor substrates of the glycosyltransferases alter to a noticeable extent during the oncogenic process. This may result in changes to the expression of the terminal glyco-epitopes in cancer cells (Kannagi 2004; Koike et al. 2004; Kannagi et al. 2010; Yusa et al. 2010) . As a result of these diverse and complex factors, the molecular mechanisms associated with elevation of expression of the sLe a /sLe x antigens during colon cancer oncogenesis are not well understood.
The β3GnT enzyme adds a GlcNAc moiety from donor substrate UDP-GlcNAc to the acceptor substrates in a β1-3 linkage. To date, eight different β3GnTs, designated β3GnT2 β3GnT9, each of which shows a different preference for various acceptor substrates, have been identified as belonging to the human β3GnT family (Narimatsu 2006) . β3GnT7, first identified in 2002 (Kataoka and Huh 2002) and denoted by the official gene symbol B3GNT7, has been demonstrated to effectively target keratan sulfated-related glycans; these glycans are sulfated poly-LacNAc chains mainly found in keratan sulfate (Seko and Yamashita 2004) . It has been shown that β3GnT7 and β4GalT4 are able to use sulfated poly-LacNAcs as acceptor substrates and actively extend poly-LacNAc chains (Seko et al. 2003; Kitayama et al. 2007 ). Thus, β3GnT7 and β4GalT4, together with GlcNAc 6-O-sulfotransferase (GlcNAc6ST) and Gal 6-O-sulfotransferase (Gal6ST), which are responsible for sulfation of the GlcNAc and Gal moieties in the poly-LacNAc chains, respectively (Quantock et al. 2010) , are believed to be responsible for the synthesis of extended sulfated glycans. A later investigation also has demonstrated that β3GnT7 possesses the ability to extend non-sulfated poly-LacNAc chains (Ishida et al. 2005) .
In the present investigation, the B3GNT7 gene was found to express in colon at very high levels. Further studies demonstrated that expression of the B3GNT7 gene was significantly down-regulated during colon cancers oncogenesis. The results of the present investigation suggest that suppression of B3GNT7 gene during the oncogenetic processes of colon cancer results in an elevation of sLe a /sLe x cell surface antigen expression and the metastatic potential of cancer cells.
Results
The B3GNT7 gene is abundantly expressed in normal colon tissue samples and is markedly suppressed in colon cancer samples The expression profile of the B3GNT7 gene in various human tissues was analyzed. The amounts of the B3GNT7 and GAPDH transcripts in the multiple tissue cDNA panels were quantitatively analyzed. The B3GNT7 gene was found to express abundantly in normal colon cells (Supplementary data, Figure S1 ), suggesting that the B3GNT7 gene has important functions in colon tissue. A relatively high expression of the B3GNT7 gene was also observed in pancreas, lung and placenta tissues when compared with other tissues. This profile of B3GNT7 gene expression in human tissues accords with the expression profile of the mouse B3gnt7 gene observed in various mouse tissues (Kataoka and Huh 2002) and shows that the B3GNT7 gene expression in the colon is the most abundant among all the various tissues examined.
When expression of the B3GNT7 gene in matched normal/ tumor tissue pairs from 10 patients diagnosed with Grade III adenocarcinoma of colon was examined, it was found that expression of the B3GNT7 gene was significantly suppressed in the tumor tissue samples compared with the respective matched normal tissue sample (Figure 1 ). Such suppression of B3GNT7 gene expression in colon tumor tissues was consistently observed across all the 10 matched tissue pairs examined. The mean ± standard errors of the mean (SEM) values of the B3GNT7/GAPDH quantity in the normal and tumor tissue groups are 145.8 × 10 −3 ± 30.9 × 10 −3 and 9.1 × 10 −3 ± 3.5 × 10 −3
, respectively (P = 0.003, two-tailed Student's t-test).
Analysis of methylation status in the promoter region of B3GNT7 gene in colon cancer cell lines and tumors The DNA sequence of the B3GNT7 gene is rich in C and G nucleotides, and the nucleotide region encompassing the 5′ promoter, exon 1, and part of the intron 1 fulfills the criteria for a CpG island (Gardiner-Garden and Frommer 1987) . The connection between DNA methylation of such a CG dinucleotide-rich promoter and transcriptional inactivation of the related genes is well established (Scarano et al. 2005; Klose and Bird 2006) . To explore the role of DNA methylation in the regulation of B3GNT7 expression during colon cancer oncogenesis, the methylation status of the CG dinucleotide in the promoter region of the B3GNT7 gene across the 10 matched pairs of normal/tumor colon tissues was analyzed by the bisulfite modification method. The DNA segment from nucleotide -272 to nucleotide +20 in the B3GNT7 gene, which contains 25 CG dinucleotides (Figure 2A ), was polymerase chain reaction (PCR)-amplified from bisulfite-modified genomic DNA samples prepared from each of the colon tissue pairs, and then cloned. At least 10 clones (ranging from 10 to 20) were selected for each sample and their sequences determined to examine the methylation status of the 25 CG sites in the B3GNT7 promoter region. The total methylation percentages of the 25 CG sites in each of the normal/tumor colon tissue pairs are schematically represented in Figure 2B . A higher methylation percentage in the promoter region of the B3GNT7 gene in the tumor tissue Fig. 1 . Expression of the B3GNT7 gene in 10-matched normal/tumor pairs of colon tissue. The matched pairs of normal/tumor colon tissue were taken from 10 patients diagnosed with Grade III adenocarcinoma of colon. The tumor tissues contain tumor percents ranging from 50 to 70%, and the paired normal tissues were taken from colon areas 5-15 cm from the diseased portion in each patient. The B3GNT7 and GAPDH transcript levels in each sample were analyzed using real-time PCR and TaqMan probe sets; they were quantified using standard curves for each respective transcript that were generated from serial dilutions of a plasmid vector bearing either B3GNT7 or GAPDH cDNA. The quantity of the B3GNT7 transcript was normalized against the GAPDH transcript for each sample. The means of the data obtained from three detections are presented; error bars indicate the standard deviations.
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than that in the matched normal tissue was observed across all the 10 matched tissue pairs. Statistical analysis with the R software (version 3.0.2) using Pearson's product-moment correlation coefficient revealed a significant correlation between the total methylation percentages in the promoter region and the expression levels of the B3GNT7 gene (Pearson's correlation coefficient = −0.494, P = 0.027). These results indicate that changes in DNA methylation in the promoter region of the B3GNT7 gene occur during the colon cancer oncogenetic processes, and affect the expression of the B3GNT7 gene. The data of the methylation analysis were also compiled to show the methylation incidence for each of individual CG sites in the normal and tumor colon tissues ( Figure 2C ). The methylation profiles, revealed with the methylation incidences for each individual CG site, exhibit a specific methylation pattern in the B3GNT7 promoter region in both normal and tumor colon tissues with a higher methylation frequency in the 5′ part of the region and a barely methylated region around the CG sites numbered 15 17. Association between specific CG site methylation and the expression of the B3GNT7 gene was also evaluated with the R software, and the result showed a highest correlation between the methylation of CG site numbered 7 and the expression of the B3GNT7 gene (Pearson's correlation coefficient = −0.474, P = 0.035).
The effect of the DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-aza-dC) on expression of the B3GNT7 gene and on the methylation status of the B3GNT7 promoter in the colon cancer cell lines HT-29, DLD-1 and HCT 116 were examined. An inverse relationship between the expression level of the B3GNT7 gene and the methylation level of the B3GNT7 promoter region in the cells was identified (Figure 3 ). Hypermethylation within the B3GNT7 promoter region was observed in HT-29 and DLD-1 cells, and in parallel to the hypermethylation the B3GNT7 transcript was found to be barely detectable in the HT-29 cells and to be virtually undetectable in the DLD-1 cells. When these cells were treated with 5-aza-dC, DNA methylation in the B3GNT7 promoter was decreased and transcription of the B3GNT7 gene was drastically induced. In the HCT 116 cells, the B3GNT7 promoter was not extensively methylated and expression of the B3GNT7 gene in B3GNT7 gene suppression in colon cancer these cells was found to be considerable when compared with the B3GNT7 expression levels in the HT-29 and DLD-1 cells. The methylation incidences for the individual CG sites in untreated and 5-aza-dC-treated HT-29, DLD-1 and HCT 116 cells are presented in Supplementary data, Figure S2 .
The results obtained from the various cell lines with and without 5-aza-dC treatment indicate that a relationship exists between methylation status of the B3GNT7 promoter region and the level of B3GNT7 gene expression. Together with the observations of a higher methylation incidence in the B3GNT7 promoter of colon tumor tissue samples compared with the matched normal portion, these findings reveal the functional correlation between promoter-region DNA methylation and suppression of the B3GNT7 gene expression during colon cancer oncogenesis.
Ectopic expression of the B3GNT7 gene diminishes the metastatic potential of colon cancer cells To explore the effect of B3GNT7 gene expression on the metastasis of colon cancer cells, HT-29 colon cancer cells with B3GNT7 gene ectopically expressed were established and the nude mice xenograft model was employed. As illustrated in Figure 4A , significant tumor loads were observed in the livers of six of the seven nude mice injected with the mock control HT-29 cells, while the liver tumor loads in the seven nude mice injected with the HT-29 cells with B3GNT7 gene overexpression were markedly reduced. The average weight of the livers from the mock control group (2.035 g, ranging 1.614 2.841 g) is moderately and significantly heavier than that of the livers from mice from the B3GNT7 expression group (1.651 g, ranging 1.590 1.757 g) ( Figure 4B ). The findings from the nude mice xenograft experiments show that expression of the B3GNT7 gene suppresses the metastatic potential of colon cancer cells.
Transwells experiments were employed to analyze the migration capabilities of the HT-29 cells with and without B3GNT7 over-expression. As shown in Figure 5 , the migration capability of HT-29 cells is decreased when the B3GNT7 gene is ectopically expressed in the cells. The results obtained from the cell migration assays agree with the results obtained by the nude mice xenograft model, which showed diminished metastatic potential of the HT-29 cells when there is ectopic expression of B3GNT7. The proliferation rates of the HT-29 cells with and without B3GNT7 over-expression were analyzed using a Vybrant MTT Cell Proliferation Assay Kit (Invitrogen, Carlsbad, CA) and the results showed that the growth curves of the two cell types were similar (Supplementary data, Figure S3 ), which implies that ectopic expression of B3GNT7 gene in HT-29 cells does not affect the proliferation rate of the cells. Thus, the decreased metastatic potential and lower migration capability observed in the HT-29 cells when B3GNT7 is over-expressed are not a result of an alteration in the proliferation rate of HT-29 cells.
The findings from the nude mice xenograft model and cell migration experiments, together with the observation that there is a significant and consistent down-regulation of the B3GNT7 gene in tumor tissues of Grade III colon adenocarcinoma, strongly suggest that suppression of B3GNT7 gene expression is involved in the colon cancer oncogenesis and metastasis.
Expression of B3GNT7 gene in colon cancer cells leads to a reduction in the level of sLe a and sLe x antigens on the cell surface The β3GnT7 enzyme has been demonstrated to target sulfated and non-sulfated poly-LacNAc chains; it is on the terminals of these chains that the sLe a and sLe x antigenic epitopes are built. Based on this fact, the effect of B3GNT7 expression on the presence of sLe a and sLe x cell surface antigens in colon cancer cells was explored. The expression of sLe a and sLe x antigens on the surface of HT-29 cells with and without ectopic expression of B3GNT7 gene was examined by flow cytometric analysis ( Figure 6) . A considerable amount of sLe a antigen was detected on the cell surface of control HT-29 cells and this was significantly reduced when there was ectopic expression of the B3GNT7 gene in the HT-29 cells. Suppression of sLe x antigen expression was also observed in HT-29 cells with B3GNT7 over-expression, when compared with the sLe x profile of the mock control cells, although the reduction was more moderate than with the sLe a antigen. The Le a and Le x antigens on these HT-29 cells were also analyzed and they were also found to decrease considerably when B3GNT7 over-expression was present (data not shown). The sLe a /sLe x cell surface antigens have been demonstrated to facilitate the metastasis of colon cancer cells and therefore the decrease in sLe a /sLe x cell surface antigens in HT-29 cells when there is B3GNT7 over-expression may explain the diminished metastasis potential of such cells in the nude mice xenograft model.
The effect of over-expression of the B3GNT7 gene on the expression of cell surface sLe a /sLe x antigens was also examined in DLD-1 and HCT 116 cells. Flow cytometric analysis showed that, similar to HT-29 cells, B3GNT7 over-expression led to a substantial reduction in sLe a antigen expression in DLD-1 cells (Figure 6 ). sLe x antigen was virtually undetected in original DLD-1 cells. When HCT 116 cells were examined, sLe x expression was moderately decreased when the B3GNT7 gene was ectopically expressed, which is also similar to the situation with HT-29 cells; however, sLe a expression in HCT 116 cells appeared to be unaffected by the expression of B3GNT7 gene in these cells. As shown in Figure 3A , expression of the B3GNT7 gene is virtually absent in HT-29 and DLD-1 colon cancer cells and the sLe a antigen, which is abundantly expressed on the cell surfaces of these cells, is markedly reduced in the cells with ectopic expression of the B3GNT7 gene. This phenomenon of sLe a antigen reduction when there is B3GNT7 over-expression was not observed in HCT 116 cells, which expressed a significant amount of the B3GNT7 gene intrinsically.
Discussion
The present investigation's findings suggest a link between suppression of B3GNT7 gene expression and elevation of sLe a / sLe x cell surface antigen expression; this consequently seems to increase the metastatic capability of colon cancer cells during oncogenesis. It should be noted that the mouse B3gnt7 gene was identified due to its capability of preventing cells from migration and invasion in an in vitro assay system (Kataoka et al. 2001; Kataoka and Huh 2002) ; the function of the human B3GNT7 gene observed in the present study accords with the functional role of the mouse B3gnt7 gene demonstrated in the in vitro assay.
The function of sLe a /sLe x cell surface antigens during colon cancer cell metastasis is well recognized. Nevertheless, the molecular mechanism that leads to an elevated expression of the sLe a /sLe x antigens during colon cancer oncogenesis remains obscure. Two concepts, "neo-synthesis" and "incomplete synthesis", have been proposed as the mechanisms associated with the elevation of sLe a /sLe x antigens in colon cancer cells (Kannagi 2004; Kannagi et al. 2008) . The first concept indicates that there is an induction of some glycan-related genes that consequently leads to the "neo-synthesis" of the sLe a /sLe x antigens and other adhesion molecules. This has been supported by evidence whereby expression of the fucosyltransferase 7, ST3 β-galactoside α-2,3-sialyltransferase 1 (ST3GAL1 or ST3O) and UDP-galactose transporter-1 (UGT1) genes is up-regulated in colon cancer cells; these are known to be involved in the synthesis of sLe a or sLe x epitopes (Kannagi 2004; Koike et al. 2004; Kannagi et al. 2008; Yin et al. 2010 ). It has also been shown that hypoxia and hypoxia-inducible factor are able to stimulate the expression of these glycan-related genes associated 
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with "neo-synthesis". Other evidences have suggested that the elevation of sLe a and sLe x antigens in colon cancer cells is a result of "incomplete synthesis" of glyco-structures that are usually expressed on normal colon epithelial cells (Kannagi 2004; Kannagi et al. 2008 Kannagi et al. ,2010 . In contrast to the high expression of sLe a and sLe x antigens in colon cancer tissue, relative high amounts of the disialyl-Le a [NeuAcα2-3Galβ1-3(NeuAcα2-6) (Fucα1-4)GlcNAcβ1-] and sialyl-6-sulfo-Le x [NeuAcα2-3Galβ1-4(SO 3 --6)(Fucα1-3)GlcNAcβ1-] structures have been identified among the cell surface glycans of normal colon epithelial cells (Izawa et al. 2000; Miyazaki et al. 2004) . In this context, it has been shown that expression of an α-2,6-sialyltransferase, which is involved in the formation of disialyl-Le a , is suppressed by epigenetic mechanisms during colon cancer oncogenesis and that this leads consequently in colon cancer cells to a decrease in the amount of disialyl-Le a structure present and an increase in the amount of sLe a antigen present. In addition, it has been demonstrated that gene silencing of a sulfate transporter gene, solute carrier family 26 (sulfate transporter), member 2 (SLC26A2 or DTDST), during colon cancer oncogenesis via epigenetic mechanisms is involved in a decrease in formation of sialyl-6-sulfo-Le x structures and an increase in the presence of sLe x antigen . Thus, epigenetic silencing, including DNA methylation and histone deacetylation, seems to lead to a suppression of certain biochemical pathways during colon cancer oncogenesis and this results in "incomplete synthesis" of the disialyl-Le a and sialyl-6-sulfo-Le x structures. A consequence of this is an elevation of sLe a and sLe x cell surface antigens, respectively, which then promotes the metastatic capability of the cancer cells.
The observations in the present investigation support the hypothesis that the suppression of B3GNT7 gene expression during colon cancer oncogenesis promotes the expression of sLe a /sLe x antigens on the cell surface and that this as a consequence enhances the metastasis of the cancer cells. DNA methylation in the B3GNT7 promoter region was found to play a significant role in the suppression of the B3GNT7 gene during colon cancer oncogenesis. These processes identified in the present investigation coincide with the molecular mechanisms associated with the "incomplete synthesis" for increased sLe a / sLe x antigens in colon cancer cells. Aberrant hypermethylation of gene promoters is known to be a major mechanism associated with inactivation of tumor-suppressor genes in cancers (Esteller 2005) . In colorectal cancers, epigenetic changes that affect selected genes are closely related to neoplastic transformation (Suzuki et al. 2002; Kondo and Issa 2004) , and aberrant DNA methylation appears to arise very early in colon cancer, initially even when the mucosa has a normal appearance (Ahuja et al. 1998; Toyota et al. 1999; Lao and Grady 2011) . Suppression of the B3GNT7 gene and the cellular effects of B3GNT7 gene suppression imply that this is another example of aberrant methylation associated with colon cancer oncogenesis and metastasis.
Nevertheless, the biochemical mechanisms involved in the suppressed expression of sLe a /sLe x antigens due to B3GNT7 gene over-expression in colon cancer cells await further elucidation. As described in the introduction section, it is clear that structural alterations and modifications to the poly-LacNAc chains, such as sulfation and α-2,6-sialylation, are able to significantly affect the synthesis and expression of the sLe a /sLe x antigens. The β3GnT enzyme encoded from the B3GNT7 gene has been shown to effectively target sulfated poly-LacNAc chains and to be one of the critical enzymes responsible for the synthesis of keratan sulfate glycosaminoglycans. Thus, the expression of the B3GNT7 gene may facilitate the synthesis and extension of sulfated poly-LAcNAc chains in colon tissues as well as inhibiting the formation of the sLe a /sLe x antigens. The expression of keratan sulfate in the HT-29, DLD-1 and HCT 116 cells with ectopic expression of B3GNT7 gene was examined using a monoclonal antibody against keratan sulfate, 5D4 (Seikagaku Co., Tokyo, Japan) by flow cytometric analysis; however, no increase in keratan sulfate was observed (data not shown). Other enzymes that are involved in the synthesis of keratan sulfate, such as β3GalT4, GlcNAc6ST or Gal6ST, might be required, in addition to β3GnT7, in order to form keratan sulfate in such cells. However, there remains the possibility that one or more biochemical mechanisms other than the extension of sulfated poly-LacNAc chain are involved in the suppression of sLe a /sLe x antigen expression by the β3GnT7 enzyme. This possibility cannot be excluded because a previous study has demonstrated that β3GnT7 also possesses the ability to extend non-sulfated poly-LacNAc chains (Ishida et al. 2005) . Further investigations are needed to elucidate and delineate the biochemical mechanisms involved in reducing sLe a /sLe x antigen formation/expression when there is a high level of β3GnT7 glycosyltransferase expression. These should yield significant results that will improve our understanding of the mechanisms by which an elevation of the sLe a /sLe x antigens occurs during colon cancer oncogenesis.
Materials and methods

Samples and cell lines
Human multiple tissue complementary DNA (cDNA) panels were purchased from Clontech Laboratories, Inc. (Mountain View, CA). Ten matched normal/tumor tissue pairs for colon cancer were purchased from BioServe Biotechnologies, Ltd. (Beltsville, MD). The matched pairs of normal/tumor tissue were taken from 10 patients diagnosed with stage III adenocarcinoma of colon and were snap frozen immediately after dissection. The tumor tissues contain tumor percents ranging from 50 to 70%, and the paired normal tissues were taken from areas of the colon 5-15 cm from the diseased portion in each patient. The use of human subjects in the present investigation was conducted under the tenets of the Helsinki protocol and the program approved by the Institutional Review Board of National Taiwan University. Human colon cancer cell lines HT-29, DLD-1 and HCT 116 were purchased from the American Type Culture Collection (Manassas, VA). HT-29 and DLD-1 cells were grown in 90% RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 50 units/mL of penicillin and 50 μg/mL of streptomycin. HCT 116 cells were grown in 90% Dulbecco's modified eagle media with the same supplementation.
Quantification of the B3GNT7 transcript Total RNA from normal/tumor colon tissue pairs and the various colon cancer cell lines were prepared using the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). First-strand cDNAs C-H Lu et al. were synthesized using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). The B3GNT7 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcripts in the cDNA samples were quantified using TaqMan gene expression assay kits (Applied Biosystems) with ID codes Hs00377020_m1 and Hs99999905_m1, respectively. Real-time PCR detection was performed using a Rotor-Gene 6000 (Qiagen). Serial dilutions of a plasmid vector bearing either B3GNT7 or GAPDH cDNAwere used to generate standard curves for quantifying each respective transcript in the cDNA samples.
DNA methylation analysis
Genomic DNAs from the colon tissues and the various cancer cell lines were prepared using a QIAamp DNA Mini Kit (Qiagen). The bisulfite modification method was employed to determine the methylation status of cytosine residues in the genomic DNA (Frommer et al. 1992) . Bisulfite modification of the genomic DNA samples was achieved using an EpiTect Bisulfite Kit (Qiagen). Nested PCR was used to amplify the upper strand of the bisulfite-modified DNA segment that encompasses the promoter and exon 1 regions of the B3GNT7 gene. The first round of PCR was performed using forward and reverse primers for the modified sequences, 5′-GGGTTAGA GGGAAATGGTTGG-3′ (nucleotides -287 through -267, transcription initiation nucleotide of B3GNT7 exon 1 of RefSeq Transcript NM_145236.2 in the NCBI database as +1) and 5′-CCCAACCCCACTCACCACAAC-3′ (complementary of nucleotides +186 through +206). The second round of PCR was performed using forward and reverse primers for the modified sequences, 5′-GGTTGGGTTTTGGGGTGTTTTAG-3′ (nucleotides -272 through -250) and the reverse primer 5′-TAACCCAAATACCTTAACCCCTT-3′ (complementary of nucleotides -3 through +20). The PCR-amplified DNA segments were cloned into the pGEM-T Easy vector (Promega Corp., Madison, WI). Ten to 20 clones from the PCR-amplified product were selected for each sample and their sequences determined using the Sanger method in order to estimate the incidence of methylation at the CG dinucleotides in the promoter region of the B3GNT7 gene.
Treatment of cells with DNA methylation inhibitor HT-29, DLD-1 and HCT 116 colon cancer cells were cultured in six-well plates at a density of 1 × 10 5 cells/mL. 5-Aza-dC (Sigma-Aldrich Co., St. Louis, MO), a potent and specific inhibitor of DNA methylation, was added to a final concentration of 5 μM. Cells were cultured for 6 days before harvesting of their total RNA and genomic DNA.
Ectopic expression of B3GNT7 gene A lentiviral expression system was used to ectopically express B3GNT7 gene in the various colon cancer cell lines. The full coding cDNA sequence of B3GNT7 was obtained by PCR using the primer pair 5′-caccatggctATGTCGCTGTGGAA GAAAACCGTCTACC-3′ (nucleotides +1 through +28, translational initiation codon [underlined] as +1 +3) and 5′-GAGCACCTGGAGCTTGCGGGAGCAGGTG-3′ (complementary of nucleotides +1176 through +1203), with the cDNA sample prepared from the mRNA of HT-29 cells serving as the template. The PCR-amplified DNA fragments were cloned into pLenti6/V5-D-TOPO vector (Invitrogen) in order to construct the gene transfer vector pLenti6-B3GNT7. HEK 293T cells (American Type Culture Collection), cultured in 12-well plates (2 × 10 5 cells/well), were transfected with 0.4 μg of the pLenti6-B3GNT7 transfer construct, together with the packaging vector pCMVdeltaR8.91 (0.4 μg) and the VSV-G envelope glycoprotein-expressing vector pMD.G (0.4 μg) ( provided by the National RNAi Core Facility, Academia Sinica, Taiwan) using Lipofectamine Transfection Reagent supplemented with Plus Reagent (Invitrogen). Medium was collected 48 hours after transfection, and the virion suspensions were concentrated by centrifugation. HT-29, DLD-1 and HCT 116 cells, cultured in 24-well plates (1 × 10 5 cells/well), were then transduced with the produced virions in a medium to which polybrene was added to a final concentration of 8 μg/mL. The cells were transferred to six-well plates 16 h after transduction, and were then cultured for 72 h before being harvested. Similar procedures were used to transduce HT-29, DLD-1 and HCT 116 cells with virions produced from the mock pLenti6 vector in order to establish mock control cells.
Nude mice xenograft experiment A total of 2 × 10 6 HT-29 cells with ectopic expression of the B3GNT7 gene were suspended in 50 μL of RPMI 1640 medium and injected via intra-splenic route into each of seven 8-week-old male nude mice (BALB/cAnN.Cg-Foxn1 nu / CrlNarl, obtained from National Laboratory Animal Center of National Applied Research Laboratories, Taiwan). Another group of seven nude mice were injected with mock control HT-29 cells. Forty-five days postinjection, the mice were sacrificed and the livers of the mice were dissected; the tumor loads in the livers were observed and all the livers were weighted.
Cell migration assays
The migration capability of the cells was analyzed using Transwell Permeable Supports ( polycarbonate membranes with 8 μm pore sizes) (Corning Incorporated Life Sciences, Tewksbury, MA), which is based on the Boyden chamber principle (Boyden 1962) . Briefly, 5 × 10 4 of HT-29 cells with ectopic expression of B3GNT7 gene and the mock control HT-29 cells were seeded in 24-well Transwell inserts, and culture medium supplemented with 10% of FBS were added to the bottom wells, while serum-free medium were added to the top wells. After 48 h, the cells that had migrated through the Transwell membranes were stained with 0.5% of crystal violet (in 20% methanol/phosphate-buffered saline [PBS]) after fixation and permeablization using 3.7% formaldehyde/PBS and methanol, respectively. The cells present were quantified by dissolving the adsorbed dye in the cells into a solution of 33% acetic acid/PBS and measuring absorbance at 630 nm using a spectrophotometer (Gillies et al. 1986 ).
Flow cytometry analysis
To detect the sLe a and sLe x cell surface antigens, cells were incubated with monoclonal mouse antibodies against sLe a (Calbiochem, EMD Millipore Corp., Billerica, MA) or sLe x (BD Biosciences, San Jose, CA), respectively, at 4°C for 2 h after B3GNT7 gene suppression in colon cancer blocking with 5% bovine serum albumin. The bound anti-sLe a or anti-sLe x antibodies were detected by incubation with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Leinco Technologies, St Louis, MO) and FITC-conjugated goat antimouse IgM antibody (Santa Cruz Biotechnology, Santa Cruz, CA), respectively. Finally, the cells were subjected to flow cytometry on a FACSCalibur (BD Biosciences) or an Epics XL (Beckman Coulter, Fullerton, CA).
Supplementary data
Supplementary data are available at http://glycob.oxfordjournals.org/ online.
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